An Improved Case of Autism as Revealed by PET CT Scan in Patient Transplanted with Autologous Bone Marrow Derived Mononuclear Cells

Sharma, Alok; Badhe, Prerna

doi:10.4172/2157-7633.1000139

Cited by 14 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant improvements were observed over a period of 6 mo to 1 year (social interaction and emotions, impulse control, reading skills, tracing, recognition of all shapes and following commands, and hyperactivity). Interestingly, comparisons of pre/post cell therapy brain positron emission tomography scans revealed a markedly increased uptake in bilateral temporal lobes and bilateral calcarine cortices with mild increased uptake in the left medial pre-frontal cortex [43] . Transplanted stem cells therefore seemed to ameliorate neural hypoperfusion in the previous case report.…”

Section: Mesenchymal Stem Cells In Treating Autism: Clinical Evidencementioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal stem cells in treating autism: Novel insights

Siniscalco

Bradstreet

Sych

et al. 2014

WJSC

View full text Add to dashboard Cite

Autism spectrum disorders (ASDs) are complex neurodevelopmental disorders characterized by dysfunctions in social interactions, abnormal to absent verbal communication, restricted interests, and repetitive stereotypic verbal and non-verbal behaviors, influencing the ability to relate to and communicate. The core symptoms of ASDs concern the cognitive, emotional, and neurobehavioural domains. The prevalence of autism appears to be increasing at an alarming rate, yet there is a lack of effective and definitive pharmacological options. This has created an increased sense of urgency, and the need to identify novel therapies. Given the growing awareness of immune dysregulation in a significant portion of the autistic population, cell therapies have been proposed and applied to ASDs. In particular, mesenchymal stem cells (MSCs) possess the immunological properties which make them promising candidates in regenerative medicine. MSC therapy may be applicable to several diseases associated with inflammation and tissue damage, where subsequent regeneration and repair is necessary. MSCs could exert a positive effect in ASDs through the following mechanisms: stimulation of repair in the damaged tissue, e.g. , inflammatory bowel disease; synthesizing and releasing anti-inflammatory cytokines and survival-promoting growth factors; integrating into existing neural and synaptic network, and restoring plasticity. The paracrine mechanisms of MSCs show interesting potential in ASD treatment. Promising and impressive results have been reported from the few clinical studies published to date, although the exact mechanisms of action of MSCs in ASDs to restore functions are still largely unknown. The potential role of MSCs in mediating ASD recovery is discussed in light of the newest findings from recent clinical studies.

show abstract

Section: Mesenchymal Stem Cells In Treating Autism: Clinical Evidencementioning

confidence: 99%

“…Intrathecally transplanted autologous bone marrowderived mononuclear cells were efficacious in improving the quality of life in a 14-year-old boy with severe autism [43] . A detailed cell-sorting analysis was not done, but the cell extract contained a percentage of MSCs.…”

Section: Mesenchymal Stem Cells In Treating Autism: Clinical Evidencementioning

confidence: 99%

Mesenchymal stem cells in treating autism: Novel insights

Siniscalco

Bradstreet

Sych

et al. 2014

WJSC

View full text Add to dashboard Cite

show abstract

“…Initially, Sharma et al [112] used autologous bone marrow mononuclear cells (BMMNC) intrathecally in a 14-year-old boy, noting symptomatic improvement, with a change in CARS from severely autistic to nonautistic and enhanced brain function on positron emission tomography-computed tomography (PET-CT).…”

Section: Cell Therapymentioning

confidence: 99%

Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy

Marchezan

Santos

Deckmann

et al. 2018

Neuroimmunomodulation

View full text Add to dashboard Cite

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with an unknown etiology and currently few effective therapies. Immune system alterations have being demonstrated in ASD, both in humans and via animal models; immune imbalance thus arises as a possible pathway for drug intervention. In this review, the studies were classified into 2 major groups: (1) clinical research whose authors classify therapies with primary anti-inflammatory and immunomodulatory actions, making use of: sulforaphane, celecoxib, lenalidomide, pentoxifylline, spironolactone, flavonoid luteolin, corticosteroids, oral immunoglobulin, intravenous immunoglobulin, cell therapy, dialyzable lymphocyte extracts, minocycline, and pioglitazone; and (2) other ASD therapies already used or currently under study whose initial characteristics were neither anti-inflammatory nor immunomodulatory initially, but displayed a capacity for immunomodulation throughout the treatment: risperidone, vitamin D, omega-3, Ginkgo biloba, L-carnosine, N-acetylcysteine, and microbiome restoration. These studies used various data acquisition methodologies. Questions arose such the need for randomized and placebo-controlled studies with greater numbers of participants as well as the use of biomarkers to refine the treatment of autistic subjects.

show abstract

“…In addition to the above study, we have also published eight case reports demonstrating the safety, efficacy and objective improvements on PET-CT scan brain in patients with autism following stem cell therapy [61][62][63][64][65][66][67][68].…”

Section: Clinical Evidencementioning

confidence: 99%

“…Overall, 122 patients were administered with cellular therapy and 90 showed improvements ( Table 2) [58][59][60][61][62][63][64][65][66][67][68]. Physical Disabilities -Therapeutic Implicationsscores and 20 patients (62%) showed decreased severity on CGI-I.…”

Section: Clinical Evidencementioning

confidence: 99%

Stem Cell Therapy in Pediatric Neurological Disabilities

Sharma¹,

Sane²,

Gokulchandran³

et al. 2017

Physical Disabilities - Therapeutic Implications

Self Cite

View full text Add to dashboard Cite

Pediatric neurological disorders represent a major part of the disabilities worldwide. In over 10 decades of research to find a cure for these disorders, medical science has not been able to repair the underlying brain injury. This chapter focuses on recent advances in the application of stem cells as a therapeutic tool for some of the common neurodevelopmental disorders (cerebral palsy, autism, intellectual disability and muscular dystrophy). The mechanism of action of stem cells in each disorder has been explained. A review of clinical data has been described giving a clear understanding of current status of stem cell therapy in these disorders. Various factors influencing the outcome of stem cell therapy such as different types of cells, different routes of administration and dosage and frequency of transplantation have also been discussed. Our experience of treating these disorders is exhibited in the form of our published data. Use of novel monitoring tools such as MRI MSK and PET-CT scan brain to track the changes occurring at cellular level after stem cell therapy are described. We also highlight the importance of a multidisciplinary approach of combining rehabilitation with stem cell therapy.

show abstract

An Improved Case of Autism as Revealed by PET CT Scan in Patient Transplanted with Autologous Bone Marrow Derived Mononuclear Cells

Cited by 14 publications

References 15 publications

Mesenchymal stem cells in treating autism: Novel insights

Mesenchymal stem cells in treating autism: Novel insights

Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy

Stem Cell Therapy in Pediatric Neurological Disabilities

Contact Info

Product

Resources

About